Alexandra Sevko
Overview
Explore the profile of Alexandra Sevko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sevko A, Prevosto C, Ragavan S, Domingos-Pereira S, Cesson V, Carrera M, et al.
BMC Urol
. 2024 Dec;
24(1):276.
PMID: 39709428
Background: Urine biomarkers are crucial for monitoring patient responses in treating urological pathologies, including non-muscle invasive bladder cancer (NMIBC). Yet, analysing urine biomarkers poses several challenges, including ensuring specimen stability...
2.
Carrera M, Sevko A, Glanville N, Deban L
Eng Biol
. 2024 Oct;
8(2-3):31-40.
PMID: 39473536
Living cures are cell-based, programmable therapies that integrate the latest learnings in immunology and synthetic biology. Although Adoptive Cell Therapies (ACTs) have transformed the treatment landscape of haematological malignancies by...
3.
Anderson V, Brilha S, Weber A, Pachnio A, Wiedermann G, Dauleh S, et al.
J Immunother
. 2023 Feb;
46(4):132-144.
PMID: 36826388
Adoptive cell therapy with T cells expressing affinity-enhanced T-cell receptors (TCRs) is a promising treatment for solid tumors. Efforts are ongoing to further engineer these T cells to increase the...
4.
Ge Y, Bohm H, Rathinasamy A, Xydia M, Hu X, Pincha M, et al.
Cancer Immunol Res
. 2019 Nov;
7(12):1998-2012.
PMID: 31672785
Endogenous antitumor effector T-cell responses and immune-suppressive regulatory T cells (Treg) critically influence the prognosis of patients with cancer, yet many of the mechanisms of how this occurs remain unresolved....
5.
Hassel J, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, et al.
Oncoimmunology
. 2017 Sep;
6(9):e1326440.
PMID: 28932631
Myeloid-derived suppressor cells (MDSCs) are known to play a critical role in the suppression of T cell antitumor responses. Our preclinical data showed that the phosphodiesterase (PDE)-5 inhibitor sildenafil impaired...
6.
Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al.
Mol Cell
. 2017 Feb;
65(4):730-742.e5.
PMID: 28212753
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known for specifically killing cancer cells, whereas in resistant cancers, TRAIL/TRAIL-R can promote metastasis via Rac1 and PI3K. It remains unknown, however,...
7.
Shimizu Y, Peltzer N, Sevko A, Lafont E, Sarr A, Draberova H, et al.
Hepatology
. 2017 Jan;
65(6):1963-1978.
PMID: 28120397
Conclusion: The linear ubiquitin chain assembly complex serves as a previously undescribed tumor suppressor in the liver, restraining TNFR1-independent apoptosis in hepatocytes which, in its absence, is causative of TNFR1-mediated...
8.
Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al.
Clin Cancer Res
. 2015 Aug;
21(24):5453-9.
PMID: 26289067
Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic melanoma. Because only around 20% of patients experience long-term benefit, reliable markers are needed to predict a clinical response....
9.
Ridder K, Sevko A, Heide J, Dams M, Rupp A, Macas J, et al.
Oncoimmunology
. 2015 Jul;
4(6):e1008371.
PMID: 26155418
Extracellular vesicles (EVs) have been shown to transfer various molecules, including functional RNA between cells and this process has been suggested to be particularly relevant in tumor-host interactions. However, data...
10.
Umansky V, Sevko A, Gebhardt C, Utikal J
J Dtsch Dermatol Ges
. 2014 Sep;
12(11):1021-7.
PMID: 25263083
Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is...